Related Experiment Video
Updated: Jun 6, 2025

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
Priapism in the paediatric and adolescent population
Anah Mushtaq1, Sudhindra Jayasimha2, Wilson King Lim To2
1Department of General Surgery Maidstone and Tunbridge Wells NHS Trust Tunbridge Wells Hospital, Tunbridge Wells, TN2 4QJ, UK.
Priapism, a prolonged erection, is a medical emergency in children and adolescents, often linked to sickle cell disease. Prompt diagnosis and treatment are crucial to prevent long-term complications like erectile dysfunction.
Area of Science:
- Pediatric Urology
- Adolescent Medicine
- Hematology
Background:
- Priapism is defined as a penile erection lasting over 4 hours, unrelated to sexual stimulation.
- It affects males of all ages with an incidence of 0.3-1.5 per 100,000 annually.
- The condition presents in three main types: ischemic, non-ischemic, and stuttering.
Purpose of the Study:
- To review current knowledge on priapism in pediatric and adolescent populations.
- To highlight the importance of accurate diagnosis and emergent management.
- To discuss management pathways for affected individuals.
Main Methods:
- Literature review of current knowledge on pediatric and adolescent priapism.
Main Results:
- Sickle cell disease is the most common cause of priapism in children.
- Ischemic priapism, often associated with sickle cell disease, is a urological emergency.
- Delayed management of priapism can lead to erectile dysfunction.
Conclusions:
- Accurate diagnosis and emergent management are paramount in pediatric and adolescent priapism cases.
- Understanding the specific causes, like sickle cell disease, is key to effective treatment.
- Preventing delayed management is critical to avoid long-term sequelae such as erectile dysfunction.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

